166 related articles for article (PubMed ID: 37626310)
1. Intrinsic disorder in PRAME and its role in uveal melanoma.
Antonietti M; Gonzalez DJT; Djulbegovic M; Dayhoff GW; Uversky VN; Shields CL; Karp CL
Cell Commun Signal; 2023 Aug; 21(1):222. PubMed ID: 37626310
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic disorder may drive the interaction of PROS1 and MERTK in uveal melanoma.
Djulbegovic M; Taylor Gonzalez DJ; Antonietti M; Uversky VN; Shields CL; Karp CL
Int J Biol Macromol; 2023 Oct; 250():126027. PubMed ID: 37506796
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic Disorder in BAP1 and Its Association with Uveal Melanoma.
Djulbegovic MB; Taylor DJ; Uversky VN; Galor A; Shields CL; Karp CL
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292588
[TBL] [Abstract][Full Text] [Related]
4. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
5. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
6. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
8. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.
Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M
Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079
[TBL] [Abstract][Full Text] [Related]
10. Structural Protein Analysis of Driver Gene Mutations in Conjunctival Melanoma.
Djulbegovic MB; Uversky VN; Harbour JW; Galor A; Karp CL
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34681018
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
Lamas NJ; Lassalle S; Martel A; Nahon-Estève S; Macocco A; Zahaf K; Lalvee S; Fayada J; Lespinet-Fabre V; Bordone O; Pedeutour F; Baillif S; Hofman P
Pathology; 2023 Dec; 55(7):929-944. PubMed ID: 37863710
[TBL] [Abstract][Full Text] [Related]
12. PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.
Gelmi MC; Gezgin G; van der Velden PA; Luyten GPM; Luk SJ; Heemskerk MHM; Jager MJ
Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):36. PubMed ID: 38149971
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic disorder in proteins associated with oxidative stress-induced JNK signaling.
Gehi BR; Gadhave K; Uversky VN; Giri R
Cell Mol Life Sci; 2022 Mar; 79(4):202. PubMed ID: 35325330
[TBL] [Abstract][Full Text] [Related]
15. Association of Ultrasound Features in Uveal Melanoma With Metastatic Risk as Defined by Preferentially Expressed Antigen in Melanoma Status.
Rusakevich AM; Schefler AC; Zhou B; Brown A; Robe C; Bretana ME
Ophthalmic Surg Lasers Imaging Retina; 2022 Jul; 53(7):374-378. PubMed ID: 35858230
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients.
Kumar N; Singh MK; Singh L; Lomi N; Meel R; Pushker N; Sen S; Kashyap S
Hum Cell; 2023 Jan; 36(1):342-352. PubMed ID: 36282437
[TBL] [Abstract][Full Text] [Related]
17. Rapid prediction and analysis of protein intrinsic disorder.
Dayhoff GW; Uversky VN
Protein Sci; 2022 Dec; 31(12):e4496. PubMed ID: 36334049
[TBL] [Abstract][Full Text] [Related]
18. The dark proteome of cancer: Intrinsic disorderedness and functionality of HIF-1α along with its interacting proteins.
Garg N; Kumar P; Gadhave K; Giri R
Prog Mol Biol Transl Sci; 2019; 166():371-403. PubMed ID: 31521236
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic Disorder in the Human Tear Proteome.
Taylor Gonzalez DJ; Djulbegovic M; Antonietti M; Cordova M; Dayhoff GW; Mattes R; Galor A; Uversky VN; Karp CL
Invest Ophthalmol Vis Sci; 2023 Aug; 64(11):14. PubMed ID: 37561450
[TBL] [Abstract][Full Text] [Related]
20. Analyzing IDPs in Interactomes.
Uversky VN
Methods Mol Biol; 2020; 2141():895-945. PubMed ID: 32696395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
